MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-21-2024
Landos Biopharma Accounts Payables 2011-2026 | LABP
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.38 M | 3.44 M | 12.9 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.9 M | 1.38 M | 5.91 M |
Quarterly Accounts Payables Landos Biopharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.14 M | 1.03 M | 2.3 M | 3.44 M | 3.2 M | 4.71 M | 9.8 M | 12.9 M | 10.1 M | 10.7 M | 8.2 M | 8.61 M | 8.61 M | 8.61 M | 8.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.9 M | 1.03 M | 6.8 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Amgen
AMGN
|
2.37 B | $ 349.36 | 2.75 % | $ 188 B | USA |
 |
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
153 M | $ 12.67 | 2.82 % | $ 3.97 B | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 24.45 | 5.07 % | $ 3.11 B | USA |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.47 | 8.17 % | $ 391 M |  Britain |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
CymaBay Therapeutics
CBAY
|
3.83 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.72 | 5.84 % | $ 17.1 M | USA |
 |
Avid Bioservices
CDMO
|
20.7 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
3.61 M | - | - | $ 1.41 B | USA |
 |
Cabaletta Bio
CABA
|
6.64 M | $ 3.07 | - | $ 308 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.08 | 1.65 % | $ 6.7 B | Israel |
 |
Checkpoint Therapeutics
CKPT
|
6.09 M | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
28 M | $ 1.93 | 4.89 % | $ 368 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
3.38 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
2.61 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
2.01 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
617 K | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
1.44 M | $ 2.82 | 2.55 % | $ 7.36 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
26.5 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
9.06 M | - | - | $ 2.02 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
390 K | $ 3.47 | -0.29 % | $ 8.74 M | USA |